GLP-1 receptor agonist (once-weekly)
Dulaglutide
FDA-approved
Written by pep4U Editorial Team · Last reviewed July 8, 2026
A once-weekly injectable GLP-1 medication used to manage type 2 diabetes and, off-label, to support weight loss.
| Class / type | GLP-1 receptor agonist (once-weekly) |
|---|
| Category | Metabolic & Weight |
|---|
| Status (Jul 2026) | FDA-approved |
|---|
How it works
Mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. This lowers blood sugar and reduces appetite.
Known / used for
FDA-approved for glycemic control in type 2 diabetes and reducing major cardiovascular events; used off-label for weight management.
Positives
Improves blood sugar control and A1c, provides cardiovascular risk reduction, and produces modest weight loss with convenient once-weekly dosing.
Negatives & risks
Common side effects include nausea, vomiting, diarrhea, and reduced appetite; carries a boxed warning for thyroid C-cell tumors seen in rodents and risk of pancreatitis.
What people like most (reported community sentiment - not endorsement)
Users report appreciating the once-weekly schedule, steady appetite reduction, and meaningful A1c improvements.
Frequently asked questions
What is Dulaglutide?
A once-weekly injectable GLP-1 medication used to manage type 2 diabetes and, off-label, to support weight loss. Mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. This lowers blood sugar and reduces appetite.
What is Dulaglutide used or researched for?
FDA-approved for glycemic control in type 2 diabetes and reducing major cardiovascular events; used off-label for weight management.
Is Dulaglutide FDA-approved or legal?
FDA-approved: marketed as Trulicity (approved 2014) for type 2 diabetes and cardiovascular risk reduction.
What are the main risks or downsides of Dulaglutide?
Common side effects include nausea, vomiting, diarrhea, and reduced appetite; carries a boxed warning for thyroid C-cell tumors seen in rodents and risk of pancreatitis.
Legal / regulatory status
FDA-approved: marketed as Trulicity (approved 2014) for type 2 diabetes and cardiovascular risk reduction.
Recommended supplies
See all supplies →As an Amazon Associate we earn from qualifying purchases.
← Back to Metabolic & Weight